Klientu atbalsts: 27018494

Pathophysiology, Pharmacology and Biochemistry of Dyskinesia, Volume 98 [Hardback]

Volume editor Jonathan Brotchie, Volume editor Peter Jenner (Emeritus Professor of Pharmacology, Institute of Pharmaceutical Sciences, Kings College London, London, UK), Volume editor Erwan Bezard

Formāts: Hardback, 664 pages, height x width: 229x152 mm, weight: 1020 g
Sērija : International Review of Neurobiology
Izdošanas datums: 02-Nov-2011
Izdevniecība: Academic Press Inc
ISBN-10: 012381328X
ISBN-13: 9780123813282

Citas grāmatas par šo tēmu:

Neurology & clinical neurophysiology - (Noliktavā: 6 punkts)

Hardback
Cena: 185,19 €*
* Šī grāmata vairs netiek publicēta. Jums tiks paziņota lietotas grāmatas cena
Šī grāmata vairs netiek publicēta. Jums tiks paziņota lietotas grāmatas cena.
Daudzums:
- - 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
Ielikt grozā
Pievienot vēlmju sarakstam

Formāts: Hardback, 664 pages, height x width: 229x152 mm, weight: 1020 g
Sērija : International Review of Neurobiology
Izdošanas datums: 02-Nov-2011
Izdevniecība: Academic Press Inc
ISBN-10: 012381328X
ISBN-13: 9780123813282

Citas grāmatas par šo tēmu:

Neurology & clinical neurophysiology - (Noliktavā: 6 punkts)

Permanent link: https://www.kriso.lv/db/9780123813282.html

Keywords:

Movement disorders

Published since 1959, International Review of Neurobiology is a well-known series appealing to neuroscientists, clinicians, psychologists, physiologists, and pharmacologists. Led by an internationally renowned editorial board, this important serial publishes both eclectic volumes made up of timely reviews and thematic volumes that focus on recent progress in a specific area of neurobiology research. This volume reviews existing theories and current research surrounding the movement disorder Dyskinesia.

Leading authors review state-of-the-art in their field of investigation and provide their views and perspectives for future research

Chapters are extensively referenced to provide readers with a comprehensive list of resources on the topics covered

All chapters include comprehensive background information and are written in a clear form that is also accessible to the non-specialist

Recenzijas

"Invaluable reading." --NATURE

"A valuable addition to any library as current reference material for advanced undergraduates, graduate students, and professional scientists." --CHOICE

Papildus informācija

Invited experts provide authoritative reviews of existing theories and new developments

Contributors

xiii

Preface

xvii

An Introduction to Dyskinesia---the Clinical Spectrum

Ainhi D. Ha

Joseph Jankovic

I Introduction

(1)

II Akathisia

(1)

III Ballism

(1)

IV Chorea

(4)

V Dystonia

(1)

VI Jumpy Stumps

(1)

VII Levodopa-Induced Dyskinesias

(5)

VIII Assessment of Dyskinesia

(1)

IX Moving Toes and Moving Fingers

(1)

X Myoclonus

(1)

XI Myokymia

(1)

XII Myorhythmia

(1)

XIII Stereotypy

(1)

XIV Tardive dyskinesia

(2)

XV Ties

(2)

XVI Tremor

(1)

XVII Conclusion

(12)

References

(10)

L-dopa-induced Dyskinesia---Clinical Presentation, Genetics, and Treatment

L.K. Prashanth

Susan Fox

Wassilios G. Meissner

I Introduction

(1)

II Historical Aspects

(1)

III Epidemiology

(1)

IV Risk Factors

(1)

V Genetics of Dyskinesia

(1)

VI Classification

(2)

VII Clinical Characteristics

(2)

VIII Treatment

(16)

References

(9)

Experimental Models of L-DOPA-induced Dyskinesia

Tom H. Johnston

Emma L. Lane

I Historical Development of a Model of L-DOPA-Induced Dyskinesia

(1)

II MPTP-Lesioned Primate Model of L-DOPA-Induced Dyskinesia

(13)

III Unilateral 6-OHDA Lesioned Rodent Model of L-DOPA-Induced Dyskinesia

(5)

IV Critique of Toxin-Based Models of L-DOPA-Induced Dyskinesia

(2)

V Alternative Models of L-DOPA-Induced Dyskinesia

(1)

VI Future Modeling of L-DOPA-Induced Dyskinesia

(1)

VII Conclusions

(17)

References

(17)

Molecular Mechanisms of L-DOPA-induced Dyskinesia

Gilberto Fisone

Erwan Bezard

I Introduction

(1)

II Basal Ganglia and Medium Spiny Neurons

(1)

III LID and Hyperactivity of DIR/cAMP Signaling

(4)

IV Increased ERK Signaling in LID: Transcriptional and Translational Changes

102

(3)

V Glutamate NMDA Receptors and LID

105

(1)

VI Mglur5

106

(1)

VII Controlling Dyskinesia by Acting on the MSNs of the Indirect Pathway

106

(3)

VIII Cannabinoid CB1 Receptors

109

(1)

IX Pre-Synaptic Mechanisms: Serotonin Receptors

109

(2)

X Conclusions

111

(13)

Acknowledgments

112

(1)

References

112

(12)

New Approaches to Therapy

Jonathan Brotchie

Peter Jenner

I Introduction

124

(1)

II Factors that Control the Priming and Expression of LID

125

(2)

III Modifying LID Through Dopaminergic Approaches

127

(7)

IV Nondopaminergic Approaches to LID

134

(9)

V Conclusions

143

(8)

References

143

(8)

Surgical Approach to L-DOPA-induced Dyskinesias

Tejas Sankar

Andres M. Lozano

I Introduction

151

(1)

II Brief Overview of LID

152

(4)

III Surgical Treatment of LID: Efficacy and Mechanisms of Action by Target

156

(6)

IV Surgical Approach to the Patient With LID

162

(3)

V Conclusion

165

(8)

References

165

(8)

Clinical and Experimental Experiences of Graft-induced Dyskinesia

Emma L. Lane

I Introduction

173

(1)

II Transplantation for Parkinson's Disease

174

(1)

III The Clinical Phenomena of GID

175

(2)

IV Animal Models of GID

177

(1)

V Understanding the Cause of GID

178

(3)

VI Strategies for Dealing with GID

181

(1)

VII Final Considerations

182

(6)

Acknowledgments

182

(1)

References

183

(5)

Tardive Dyskinesia: Clinical Presentation and Treatment

Peter N. van Harten

Diederik E. Tenback

I Introduction

188

(2)

II Clinical Features

190

(2)

III Differential Diagnosis

192

(2)

IV Pathophysiology

194

(3)

V Tardive Dyskinesia Treatments

197

(4)

VI Prevention and Treatment of Tardive Dyskinesia in Clinical Practice

201

(3)

VII Conclusion

204

(8)

References

204

(8)

Epidemiology and Risk Factors for (Tardive) Dyskinesia

Diederik E. Tenback

Peter N. van Harten

I Introduction

212

(1)

II Spontaneous Dyskinesia in Psychiatry

213

(6)

III Discussion

219

(6)

IV Conclusion

225

(7)

Acknowledgment

226

(1)

References

226

(6)

Genetics of Tardive Dyskinesia

Heon-Jeong Lee

Seung-Gul Kang

I Introduction

232

(2)

II Genes Involved in Pharmacokinetics

234

(4)

III Genes Involved in Pharmacodynamics

238

(7)

IV Oxidative-Stress-Related Genes

245

(2)

V Other Genes Reported to be Associated with TD

247

(2)

VI The Genome-Wide Association Approach

249

(1)

VII Future Research: Copy-number Variations and Epigenetics

250

(2)

VIII TD as a Phenotype

252

(1)

IX Conclusion

253

(12)

Acknowledgment

253

(1)

References

254

(11)

Animal Models of Tardive Dyskinesia

Shrinivas Krishnarao Kulkarni

Ashish Dhir

I Introduction

265

(19)

II Limitations

284

(1)

III Conclusion

284

(5)

References

284

(5)

Surgery for Tardive Dyskinesia

Stephane Thobois

Alice Poisson

Philippe Damier

I Introduction

289

(1)

II Lesioning Surgery

290

(2)

III Deep Brain Stimulation

292

(2)

IV Conclusion

294

(4)

References

294

(4)

Huntington's Disease: Clinical Presentation and Treatment

Marianne J.U. Novak

Sarah J. Tabrizi

I Clinical Presentation and Genetics

298

(7)

II The Clinical Phenotype and its Management

305

(13)

III The Atypical Phenotype, including Juvenile Huntington's Disease

318

(1)

IV Advanced Disease and End of Life Issues

319

(1)

V Looking to the Future: Research into New Treatments for Huntington's Disease

320

(1)

VI Conclusions

320

(6)

References

321

(5)

Genetics and Neuropathology of Huntington's Disease

Anton Reiner

Ioannis Dragatsis

Paula Dietrich

I Introduction

326

(1)

II The HD Gene

327

(2)

III Normal CAG Repeat Length

329

(1)

IV CAG Repeat Length and Disease Onset and Progression

329

(1)

V CAG Repeat Instability

330

(1)

VI Genetic Modifiers of CAG Repeat Instability

330

(1)

VII Genetic Modifiers of HD Age-of-Onset

331

(2)

VIII HD: A True Dominant Gain-of-Function Disorder?

333

(1)

IX Expression of Huntingtin in Normal and HD Human Brain

334

(3)

X HD Brain Pathology and the Vonsattel Grading System

337

(2)

XI Basal Ganglia Pathology in HD

339

(10)

XII Other Telencephalic Areas in HD

349

(2)

XIII Brainstem Areas in HD

351

(2)

XIV HD and Neurogenesis

353

(1)

XV Neuroinflammatory Neuropathology in HD

354

(20)

Acknowledgments

354

(1)

References

354

(20)

Pathogenic Mechanisms in Huntington's Disease

Lesley Jones

Alis Hughes

I Introduction

374

(1)

II The HTT Gene Product

374

(12)

III The Mutant Htt Protein and its Downstream Effects

386

(12)

IV Conclusions

398

(22)

References

398

(22)

Experimental Models of HD And Reflection on Therapeutic Strategies

Jinho Kim

Olivia L. Bordiuk

Robert J. Ferrante

I Introduction

420

(3)

II Mouse Models of HD

423

(13)

III Methodological Considerations for Mouse Therapeutic Trials

436

(5)

IV Existing Clinical Management

441

(1)

V Mechanisms of Cell Death and Potential Therapeutic Targets in HD

442

(20)

VI Conclusion

462

(21)

Acknowledgments

463

(1)

References

463

(20)

Cell-based Treatments for Huntington's Disease

Stephen B. Dunnett

Anne E. Rosser

I Introduction

483

(2)

II Present Status

485

(11)

III Future Developments

496

(4)

IV Conclusion

500

(9)

Acknowledgments

501

(1)

References

501

(8)

Clinical Phenomenology of Dystonia

Carlo Colosimo

Alfredo Berardelli

I Historical Review

509

(1)

II Definition and Classification

510

(5)

III Clinical Features in Different Subtypes of Focal and Segmental Dystonia

515

(5)

IV Neuropsychiatric Features of Dystonia

520

(1)

V Conclusions

521

(5)

References

521

(5)

Genetics and Pharmacological Treatment of Dystonia

Matthew J. Barrett

Susan Bressman

I Primary Torsion Dystonia

526

(9)

II Dystonia-Plus Syndromes without Brain Degeneration

535

(3)

III Dystonia as a Feature of Degenerative Genetic Syndromes

538

(2)

IV Treatment of Dystonia

540

(12)

References

542

(10)

Experimental Models of Dystonia

Annalisa Tassone

Giuseppe Sciamanna

Paola Bonsi

Gluseppina Martella

Antonio Pisani

I Introduction

552

(1)

II Models of Genetic Engineering

553

(6)

III Spontaneous Mutants

559

(2)

IV Pharmacological and Neural Lesion Models

561

(4)

V Conclusions

565

(9)

References

566

(8)

Surgical Treatment of Dystonia

John Yianni

Alexander L. Green

Tipu Z. Aziz

I Background

574

(1)

II Classification

575

(1)

III Medical Treatment of Dystonia

576

(1)

IV Surgical Treatment of Dystonia

577

(1)

V Deep Brain Stimulation (DBS) for Dystonia

578

(3)

VI DBS for Dystonia---Clinical Overview

581

(5)

VII Conclusion

586

(5)

References

586

(5)

Index

591

(16)

Contents of Recent Volumes

607

Professor Peter Jenner is a specialist in preclinical aspects of neurodegenerative diseases, notably Parkinsons disease. He has spent the major part of his career at Kings College London where he was Head of Pharmacology for 14 years before returning to his research roots and subsequently becoming Emeritus Professor of Pharmacology. Peter has expertise in drug metabolism and pharmacokinetics but neuropharmacology based on functional models of neurodegenerative diseases has formed the major focus of his work. Peter holds a BPharm, PhD and DSc degree from the University of London. He has published well over 1000 articles with more than 700 peer reviewed papers. He is a Fellow of the Royal Pharmaceutical Society, the British Pharmacological Society, the Royal Society of Medicine and of Kings College London. Peter was recently honoured with a Doctor Honoris Causa degree from Carol Davila University of Medicine and Pharmacy, Bucharest and made an Honorary Fellow of The British Pharmacological Society for his contribution to research in to movement disorders.

Peter has worked closely with the pharmaceutical industry for many years and acts as an adviser and consultant to both major pharma and biotech companies. He has a wide knowledge of the drug discovery and drug development process and has been involved from molecule synthesis through to drug registration for use in man. Peter was the Founder, Director and Chief Scientific Officer of Proximagen, a biotech focussed on the treatment and cure of neurodegenerative diseases that was listed on AIMs and subsequently purchased by a US based healthcare company. He is a regular speaker at international meetings and also takes time to speak at Parkinsons disease patient-carer groups across the UK.

Pathophysiology, Pharmacology and Biochemistry of Dyskinesia, Volume 98 [Hardback]

Recenzijas

Papildus informācija

Konts un iestatījumi

Meklēšana

Meklēt datubāzē

Refine By

Tēmas Grāmatas angļu valodā

Izvēlieties iepirkumu grozu